China's Innovent Biologics Emerges As Immuno-Oncology Competitor With Sintilimab Approval

 
• By John Davis
  
Shanghai
China's biotech companies are an emerging force in immuno-oncology R&D • Source: Shutterstock

More from Immuno-oncology

More from Anticancer